Loading news...
Fisher Asset Management LLC trimmed its stake in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 3.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 133,465 shares of the medical research company's stock after selling 4,277 shares during the period. Fisher Asset Management LLC owned about
Retail Bank Executes Expanded $1.04M License Renewal for BIO-key Biometric Identity Solution Serving 30M Clients, cash position provides base for growth.
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the BIO Investment & Growth Summit taking place March 2-3, 2026, at the Eden Roc in Miami Beach, FL.
Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.
Bio-Rad Laboratories, Inc. (NYSE: BIO - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and.
Allianz Asset Management GmbH raised its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 22.7% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 66,549 shares of the medical research company's stock after purchasing an additional 12,310 shares during the period.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-196.
BIO-key EMEA Partners with Citadel Global to Expand India Presence & Accelerate Adoption of Identity Solutions in Support of EU–India trade agreement
BKYI: BIO-key & Visualforma awarded contract to Secure digital identities for large municipality in Portugal, enabling modern efficient citizen serivces.
Campbell and CO Investment Adviser LLC acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,240 shares of the medical research company's stock, valued at approximately
Online travel agency Expedia, our top overall contributor in Q4, drove performance in the consumer discretionary sector. Our top performers in the energy and financials sectors were NOV, a provider of oilfield equipment, technology and expertise, and First Citizens, a North Carolina-based bank. Our largest new purchase was Houston-headquartered Prosperity BancShares, the fifth-largest bank in Texas.
BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds could cap near-term upside.
ATLANTIC CITY & HOLMDEL, NJ / ACCESS Newswire / January 13, 2026 / BIO-key® International, Inc. (NASDAQ:BKYI), a leading provider of biometric enabled Identity and Access Management SaaS solutions for phoneless, tokenless, passwordless, and phish-resistant authentication, will participate at the DealFlow Discovery Conference Wednesday and Thursday, January 28th and 29th at the Borgata hotel in Atlantic City, New Jersey. Institutional investors, family offices and high-net-worth investors are invited to attend at no cost.
Insights into Parnassus Value Equity Fund (Trades, Portfolio)'s Strategic Moves in Q4 2025 Parnassus Value Equity Fund (Trades, Portfolio) recently submitted i
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, Chief Operating Officer Jon DiVincenzo, and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, January 12-15, 2026. About Bio-Rad Bio-Ra.
Shares of Bio-Rad Laboratories, Inc. (NYSE: BIO - Get Free Report) have been given a consensus rating of "Hold" by the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy